Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,806 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.
Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, Meng Z, Bai Y, Chen X, Liu X, Xiao J, Ho GF, Mao Y, Wang X, Ying J, Li J, Zhong W, Zhou Y, Siegel AB, Hao C. Qin S, et al. Among authors: mao y. J Clin Oncol. 2023 Mar 1;41(7):1434-1443. doi: 10.1200/JCO.22.00620. Epub 2022 Dec 1. J Clin Oncol. 2023. PMID: 36455168 Free PMC article. Clinical Trial.
[Comparison of lung cancer surgery in China, 2005 vs. 2015].
Li N, Tan FW, Qiu B, Li JG, Zhao J, Gao YS, Wang DL, Mao YS, Xue Q, Mu JW, Gao SG, He J. Li N, et al. Among authors: mao ys. Zhonghua Zhong Liu Za Zhi. 2018 Apr 23;40(4):300-302. doi: 10.3760/cma.j.issn.0253-3766.2018.04.012. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29730919 Chinese.
Measurement of the differential tt¯ production cross section as a function of the jet mass and extraction of the top quark mass in hadronic decays of boosted top quarks.
Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, Damanakis K, Dragicevic M, Valle AED, Hussain PS, Jeitler M, Krammer N, Lechner L, Liko D, Mikulec I, Paulitsch P, Pitters FM, Schieck J, Schöfbeck R, Schwarz D, Templ S, Waltenberger W, Wulz CE, Darwish MR, Janssen T, Kello T, Sfar HR, Mechelen PV, Bols ES, D'Hondt J, De Moor A, Delcourt M, Faham HE, Lowette S, Moortgat S, Morton A, Müller D, Sahasransu AR, Tavernier S, Doninck WV, Vannerom D, Clerbaux B, De Lentdecker G, Favart L, Hohov D, Jaramillo J, Lee K, Mahdavikhorrami M, Makarenko I, Malara A, Paredes S, Pétré L, Postiau N, Thomas L, Bemden MV, Velde CV, Vanlaer P, Dobur D, Knolle J, Lambrecht L, Mestdach G, Niedziela M, Rendón C, Roskas C, Samalan A, Skovpen K, Tytgat M, Bossche NVD, Vermassen B, Wezenbeek L, Benecke A, Bruno G, Bury F, Caputo C, David P, Delaere C, Donertas IS, Giammanco A, Jaffel K, Jain S, Lemaitre V, Mondal K, Taliercio A, Tran TT, Vischia P, Wertz S, Alves GA, Coelho E, Hensel C, Moraes A, Teles PR, Júnior WLA, Pereira MAG, Filho MBF, Malbouisson HB, Carvalho W, Chinellato J, Da Costa EM, Da Silveira GG, De Jesus Damiao D, Sousa VDS, De Souza SF, Martins J, Herrera CM, Amarilo KM, Mundim … See abstract for full author list ➔ Tumasyan A, et al. Among authors: mao j, mao y. Eur Phys J C Part Fields. 2023;83(7):560. doi: 10.1140/epjc/s10052-023-11587-8. Epub 2023 Jul 3. Eur Phys J C Part Fields. 2023. PMID: 37432714 Free PMC article.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Probing Heavy Majorana Neutrinos and the Weinberg Operator through Vector Boson Fusion Processes in Proton-Proton Collisions at sqrt[s]=13  TeV.
Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, Damanakis K, Dragicevic M, Escalante Del Valle A, Hussain PS, Jeitler M, Krammer N, Lechner L, Liko D, Mikulec I, Paulitsch P, Pitters FM, Schieck J, Schöfbeck R, Schwarz D, Templ S, Waltenberger W, Wulz CE, Darwish MR, Janssen T, Kello T, Rejeb Sfar H, Van Mechelen P, Bols ES, D'Hondt J, De Moor A, Delcourt M, El Faham H, Lowette S, Moortgat S, Morton A, Müller D, Sahasransu AR, Tavernier S, Van Doninck W, Vannerom D, Clerbaux B, De Lentdecker G, Favart L, Hohov D, Jaramillo J, Lee K, Mahdavikhorrami M, Makarenko I, Malara A, Paredes S, Pétré L, Postiau N, Starling E, Thomas L, Vanden Bemden M, Vander Velde C, Vanlaer P, Dobur D, Knolle J, Lambrecht L, Mestdach G, Niedziela M, Rendón C, Roskas C, Samalan A, Skovpen K, Tytgat M, Van Den Bossche N, Vermassen B, Wezenbeek L, Benecke A, Bruno G, Bury F, Caputo C, David P, Delaere C, Donertas IS, Giammanco A, Jaffel K, Jain S, Lemaitre V, Mondal K, Prisciandaro J, Taliercio A, Tran TT, Vischia P, Wertz S, Alves GA, Coelho E, Hensel C, Moraes A, Rebello Teles P, Aldá Júnior WL, Alves Gallo Pereira M, Barroso Ferreira Filho M, Brandao Malbouisson H, Carvalho W, Chinellato J, … See abstract for full author list ➔ Tumasyan A, et al. Among authors: mao j, mao y. Phys Rev Lett. 2023 Jul 7;131(1):011803. doi: 10.1103/PhysRevLett.131.011803. Phys Rev Lett. 2023. PMID: 37478454 Free article.
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C. Shi Y, et al. Among authors: mao y. Cancer Commun (Lond). 2021 Sep;41(9):889-903. doi: 10.1002/cac2.12179. Epub 2021 Jun 29. Cancer Commun (Lond). 2021. PMID: 34184418 Free PMC article. Clinical Trial.
[The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
Ni WJ, Deng W, Xiao ZF, Zhou ZM, Wang X, Chen DF, Feng QF, Liang J, Lyu JM, Bi N, Deng L, Zhang T, Wang WQ, Xue Q, Gao SG, Mu JW, Mao YS, Wang DL, Zhao J, Gao YS, Huang JF, Tan FW, Zhao L, Lyu F, Zhang GC. Ni WJ, et al. Among authors: mao ys. Zhonghua Zhong Liu Za Zhi. 2019 Apr 23;41(4):295-302. doi: 10.3760/cma.j.issn.0253-3766.2019.04.010. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31014056 Chinese.
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Xiong A, Ren S, Liu H, Miao L, Wang L, Chen J, Li W, Li R, Wang X, Lu Z, Wang D, Wu X, Liu Z, Xing L, Mao Y, Liu C, Zeng A, Niu H, Du Y, Sun Y, Pan Y, Hu Y, Zhang X, Chen X, Ma Z, Li N, Zhang J, Zhao M, Li X, Ye F, Li M, Yu G, Zhang X, Min J, Han D, Li J, Zhou C. Xiong A, et al. Among authors: mao y. J Thorac Oncol. 2022 Oct;17(10):1216-1226. doi: 10.1016/j.jtho.2022.06.013. Epub 2022 Jul 5. J Thorac Oncol. 2022. PMID: 35798241 Free article. Clinical Trial.
9,806 results